- Home
- WDC vs AZN Comparison
WDC vs AZN Comparison
Compare WDC & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WDC | AZN |
|---|---|---|
| Founded | 1970 | 1992 |
| Country | United States | United Kingdom |
| Employees | N/A | 96100 |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.4B | 316.4B |
| IPO Year | 1999 | N/A |
Fundamental Metrics
Financial Performance| Metric | WDC | AZN |
|---|---|---|
| Price | $526.18 | $181.68 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 22 | 1 |
| Target Price | ★ $281.77 | N/A |
| AVG Volume (30 Days) | ★ 5.2M | 1.8M |
| Earning Date | 04-30-2026 | 04-29-2026 |
| Dividend Yield | 0.12% | ★ 1.73% |
| EPS Growth | N/A | N/A |
| EPS | ★ 16.05 | N/A |
| Revenue | ★ $9,520,000,000.00 | N/A |
| Revenue This Year | $32.24 | $10.34 |
| Revenue Next Year | $26.55 | $6.43 |
| P/E Ratio | $32.21 | ★ $31.91 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $54.60 | $68.62 |
| 52 Week High | $602.54 | $212.71 |
Technical Indicators
Market Signals| Indicator | WDC | AZN |
|---|---|---|
| Relative Strength Index (RSI) | 56.99 | 45.79 |
| Support Level | $434.00 | $180.98 |
| Resistance Level | N/A | $191.50 |
| Average True Range (ATR) | 27.06 | 3.11 |
| MACD | -2.29 | 0.07 |
| Stochastic Oscillator | 54.51 | 44.73 |
Price Performance
Historical ComparisonAbout WDC Western Digital Corporation
Western Digital is a leading vertically integrated supplier of hard disk drives. The HDD market is a practical duopoly, with Western Digital and Seagate being the two largest players. Western Digital designs and manufactures its HDDs, with much of the manufacturing and workforce located in Asia. The primary consumers of HDDs are data centers.
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.